I just read this e-book, simply because, according to my friend this book is written by some of the ingenious individuals who foresaw and also profited even from the financial collapse. - Sunita
I heard people are using this e-book as a Self-help guide to investing. I recently finished studying it, and never have experimented with any of the strategies; however they all appear to make sense. - Rajiv
A fantastic guide overall. Quite different from almost all other value investing publications because it concentrates on finding unique scenarios that are best to invest in. - Alexis
This particular e-book really opened up my eyes to some fresh opportunities and possibilities that while investing I should be looking for. Once you have read this traditional value investing book you will learn a lot. - Kavita
I really like the writer of this book. It is simple, properly explained, amusing, relevant, and incredibly well planned. This particular e-book is really a holy bible for dealing with unique circumstances in the market. - Saurabh

History of Matrix Laboratories Ltd.

Herren Drugs and Pharmaceuticals Limited was incorporated as a private limited Comp. on November 29, 1984 & was subsequently converted to a public limited Comp. on August 29, 1992 for manufacture of bulk drugs.

The Comp. commenced its commercial production in October, 1989 with an installed capacity of 72 TPA & has increased its capacity to 252 TPA in Sept, 1993 & has been involved in the production of Ibuprofen, Sulphamethoxazole [SMXs], Norfoxacin & Pefloxacin.

SUBSIDIARY OF THE COMPANY

The Comp. doesn't have any subsidiaries.

GROUP PROFILE

HERREN DRUGS and PHARMACEUTICALS LIMITED is the flagship Comp. of Herren Group, founded by Mr.Sarat Gopal.

Besides Herren Drugs a Pharmaceuticals Ltd., Mr.Sarat Gopal has also successfully promoted four other Bulk Drug & Intermediate manufacturing units, M/s.Dolphin Drugs [Ps] Ltd., United Intermediaries and Chemicals [Ps] Limited, Dymes Engineers [Ps] Limited & M/s.Dymes Exports Ltd.

The Group owes its success & growth largely to its Promoters for their dynamic vision & total dedication.

With a modest turnover of Rs.25.00 lakhs in the year 1989-90 the Group has enjoyed a steady growth resulting in a total turnover of Rs.25.00 crores for year ended 31st March 1994.

2002

-N Prasad appointed as MD of Matrix Lab.

-Matrix Lab & Medicorp form a strategic alliance to establish a strong presence in the Global Active Pharmaceutical Ingredient.

2003

-Matrix Laboratories announces the change in the designation of whole time directors: 1. Mr.M Ravinder as Executive Vice-President. 2. Mr R Sundara Rajan as Executive Vice-President.

-Matrix Laboratories completes merger of Vorin Labs & Medicorp India with it.

-Matrix Lab receives approval from US Food & Drug Administrations for fluconazole Active Pharmaceutical Ingredient.

-Matrix Lab submits application for drug master files for seven of Comp. produts in the US markets.

-Lundbeck withdraws allegations of Forgery made against Matrix Laboratories

-Signed agreement with William J Clinton Presidential Foundation for supply of Antiretroviral for treatment of HIV & AIDs patients in certain developing countries.

To issue 22,50,000 equity shares at Rs 1500/- per share aggregating to Rs 3375 mn on Preferential basis to Newbridge Capital & other investors subject to shareholders approval.

To issue 'No Objection' to New Bridge Capital & other investors to enable them approach Foreign Investment Promotion Board [FIPBs], to obtain their approval for purchase of 18,00,000 equity shares from the existing shareholders through a secondary sale and

To convene an Extraordinary Meeting of members of Comp. on January 29, 2004 for aforesaid purpose.

2004

-Gets USFDA nod for manufacturing facility located at Jeedimetlla

-Matrix Labs inks pact with India Newbridge Investments

-Matrix Labs appoints Dr. C Satyanarayana as BoD

2005

-Matrix in strategic alliance with MCHEM of China

- Receives US FDA approval for its Active Pharmaceutical Ingredients [APIss] manufacturing facility located at Kazipally [Unit-IIs], near Hyderabad. Commissioned in 2004, the facility currently manufactures anti-retrovirals [ARVss] for treatment of HIV / AIDS.

2007

- Matrix Laboratories Ltd has got tentative clearance from the US Food & Drug Administration [USFDAs] under the President Emergency Plan for AIDS Relief [PEPFARs] for its Abbreviated New Drug Application [ANDAs] for Tenofovir Disoproxil Fumarate tablets, 300 mg.